[ET Net News Agency, 21 January 2021] Daiwa Research initiated coverage on JD Health
International (JDH) (06618) with a "hold" rating and a target price of HK$148.2.
The research house said JDH is an early mover among China's HealthTech digital new
infrastructure creators. Daiwa views online health services as the "new infrastructure"
that enables external parties with new online business models, and an online pharmacy as
the cash cow that funds the former.
Despite rapid GMV growth for its online pharmacy business (based on existing
infrastructure), Daiwa sees longterm upside in its online health services (new
infrastructure creator), which serves as the digital new infrastructure for potential
HealthTech ecosystems and new business models.
It sees JDH enjoying synergies from its parent in creating digital new infrastructure,
including (1) traffic - JDH can reach the group's over 400m active user accounts, (2)
logistics - JDH provides customers with an enriched product offering and quality delivery
services, leveraging on JD Group's extensive supply chain and national fulfilment network,
and (3) technology - backed by JD Group's core technologies, JDH can further improve its
digitalisation solutions for other healthcare participants. (KL)